- Chemotherapy
- Radiation Therapy
- Hormonal Therapy
- Surgery
Endometrial Cancer Treatment Market size was valued at USD 26.8 billion in 2021, growing at a CAGR of 4.8% during the forecast period 2022-28. Endometrial cancer is the most common female genital cancer that begins in endometrium of the uterus. Signs and symptoms may include vaginal bleeding and pelvic pain. Usually diagnosed by the pelvic examination, ultrasound scanning and other techniques. Treatment may include, chemotherapy, radiation therapy or hormonal therapy.  This report studies global endometrial cancer treatment market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global endometrial cancer treatment market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in global endometrial cancer treatment products.In September 2019, the US FDA approved Merck’s anti-programmed cell death protein 1 (PD-1) Keytruda and Eisai’s kinase inhibitor Lenvima for certain advanced endometrial carcinoma patients. On May 30, 2019, AbilityPharma (Ability Pharmaceuticals, SL) released the first results of the currently ongoing phase 1/2a clinical trial evaluating ABTL0812 combined with carboplatin and paclitaxel in patients with endometrial cancer or non-small cell lung cancer. The results correspond to the phase 1 part of the Phase 1/2a clinical trial.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Primary drivers for endometrial cancer treatment market include increase in the prevalence of endometrial cancer and increase in awareness and availability of minimally invasive treatments such as radiation therapy. According to American Cancer Society, in 2012, about 47,130 new cases of endometrial cases were diagnosed. In addition, increase in healthcare expenditure, technological advancements and developments and advanced healthcare services also propels the market growth of endometrial cancer treatment globally. In addition growing obesity in female population also one of the risk factor for growing prevalence of endometrial cancer worldwide. However, the side effects related to the chemotherapy, divergent nature of cancer and stringent regulatory requirements for the development of new treatments for the cancer are projected to hamper the market growth over the forecast period.
The endometrial cancer treatment market is projected to expand at a CAGR of 4.8% during the forecast period
Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Ariad Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline Plc (U.K.), Hoffmann-La Roche AG (Switzerland)
North-America is the fastest-growing region for the endometrial cancer treatment market
[urltag url='request-table-of-content']